Details of the Drug

General Information of Drug (ID: DMFEGB0)

• Drug Name: Segesterone acetate; ethinyl estradiol

Indication

Disease Entry	ICD 11	Status	REF
Contraception	QA21	Approved	[1]

• Cross-matching ID: TTD ID: D06LDT

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
G-protein coupled estrogen receptor 1 (GPER1)	TTDSB34	GPER1_HUMAN	Modulator	[1]
Progesterone receptor (PGR)	TTUV8G9	PRGR_HUMAN	Modulator	[1]

Molecular Expression Atlas of This Drug

• The Studied Disease: Contraception
• ICD Disease Classification: QA21

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Progesterone receptor (PGR)	DTT	PGR	3.26E-38	-3.79	-2.5

References

• [1] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [2] Clinical pipeline report, company report or official report of lipocine.
• [3] Preclinical experience with two selective progesterone receptor modulators on breast and endometrium. Steroids. 2000 Oct-Nov;65(10-11):733-40.
• [4] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
• [5] Pharmacological profile of progestins. Maturitas. 2008 Sep-Oct;61(1-2):151-7.
• [6] Focus on anastrozole and breast cancer. Curr Med Res Opin. 2003;19(8):683-8.
• [7] Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharm... Steroids. 2008 Feb;73(2):222-31.
• [8] Contribution of functional groups of 19-nor-progestogens to binding to progesterone and estradiol-17beta receptors in rabbit uterus. Endocrinology. 1977 Jun;100(6):1579-84.
• [9] Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat Chem Biol. 2006 Apr;2(4):207-12.
• [10] In vivo effects of a GPR30 antagonist. Nat Chem Biol. 2009 Jun;5(6):421-7.
• [11] Identification of a GPER/GPR30 antagonist with improved estrogen receptor counterselectivity. J Steroid Biochem Mol Biol. 2011 Nov;127(3-5):358-66.